
Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, discusses barriers and primary care interventions.











Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, discusses barriers and primary care interventions.

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, lymphadenopathy, and persistent symptoms.

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.

TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.

TMS 2026: Approximately 21% of women initiated systemic HT after menopause, with substantial declines in treatment persistence during the first 2 years.

TMS 2026: JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for primary care physicians.

Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.

TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions in primary care settings.

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, and anxiety symptoms.

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.

TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.

In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.

ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.

Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

Topline phase 2 data showed single-dose ABCL635 reduced moderate-to-severe vasomotor symptom frequency by 83% at week 4.

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.